Combined impact of matrix metalloproteinase-3 and paraoxonase 1 55/192 gene variants on coronary artery disease in Turkish patients

Med Sci Monit. 2008 Oct;14(10):CR536-42.

Abstract

Background: We investigated the association of matrix metalloproteinase-3 (MMP-3) and paraoxonase 1 (PON1) 55/192 polymorphisms with coronary artery disease (CAD) and the number of diseased vessels in patients with CAD.

Material/methods: One hundred thirty-nine CAD patients and 119 healthy control subjects were included in the study. Genotypes for PON1 55/192 and MMP-3 5A/6A polymorphisms were determined by restriction fragment length polymorphism.

Results: Although distributions of the RR genotype of PON1 192 and the 5A5A genotype of MMP-3 were more frequent in patients, frequencies of the QQ genotype of PON1 192, the MM genotype of PON1 55, and the 6A6A genotype of MMP-3 were significantly lower in patients compared with healthy control subjects. The combined genotypes of RR/LL and/or 5A5A are increased the risk of CAD when compared with subjects who possess neither the MMP-3 5A5A nor the PON1 RR/LL genotype. While the MMP-3 5A/6A genetic variants were not associated with the number of diseased vessels, PON1 55/192 variants were associated with the number of diseased vessels.

Conclusions: The combined PON1 55/192 and MMP-3 5A/6A genetic variants are associated with CAD; PON1 seems to be connected with the number of diseased vessels, and hypertension and hyperlipidemia are related with PON1 192 and MMP-3 in CAD patients.

MeSH terms

  • Adult
  • Aged
  • Alleles
  • Aryldialkylphosphatase / genetics*
  • Coronary Artery Disease / genetics*
  • Coronary Artery Disease / pathology
  • Diabetes Mellitus / genetics
  • Female
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Hyperlipidemias / genetics
  • Hypertension / genetics
  • Male
  • Matrix Metalloproteinase 3 / genetics*
  • Middle Aged
  • Myocardial Infarction / genetics
  • Polymorphism, Genetic*
  • Polymorphism, Restriction Fragment Length
  • Turkey

Substances

  • Aryldialkylphosphatase
  • Matrix Metalloproteinase 3